Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.

Tags

information blocking, Notice, Health and Human Services Department, National Institutes of Health

Related exam domains

None matched

Source record id

2026-16443

First seen by InfoSec Signals

9/23/2026

Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.